Travelers' diarrhea (TD), although mainly a self-limiting illness, affects a large percentage of individuals when visiting endemic countries often causing disturbance of itinerary, inconvenience and additional cost. In extreme cases TD can result in hospitalization, especially in travelers with chronic illnesses. Accumulating evidence also suggests that TD may cause post-infectious irritable bowel (IBS) syndrome in around 3% of cases.
Enterotoxigenic Escherichia coli bacteria are a common cause of TD (~45% of cases). The pathogen has been a primary focus of new TD vaccine development for many years with numerous approaches taken but with little success. Currently the marketed cholera vaccine Dukoral® (J&J/Crucell) has been shown to demonstrate some protection against ETEC induced diarrhea although it is short-lived prompting some countries not to fully recommend its use for TD. Clearly a new TD vaccine with higher efficacy, broader pathogen coverage and longer protection is required not only for travelers but children in developing countries.
This MarketVIEW product is a comprehensive opportunity assessment investigating the commercial potential of hypothetical new TD vaccine for the Western travelers visiting TD endemic countries. The product consists of a detailed Executive presentation covering all relevant topics to new TD vaccine commercialization including ideal target product profile, research and clinical development issues and potential impact on Dukoral®. Also included is a detailed MS Excel value/volume demand forecast to 2030 for all relevant countries with sensitivity analysis.
This product is an ideal tool to aid early stage decision making in new TD vaccine development.